POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW)
Lung Inflammation
Synspira, Inc.OtherPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Lung Inflammation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
[68ga]ga-nota-epcd6 RenJi Hospital | N/A | D |
[18F]F-RESCA-T4 RenJi Hospital | N/A | D |
[18f]f-resca-epcd6 RenJi Hospital | N/A | D |
[68ga]ga-nota-rt4 RenJi Hospital | N/A | D |
[18f]f-resca-rt4 RenJi Hospital | N/A | D |
[68ga]ga-nota-t4 RenJi Hospital | N/A | D |
Same molecule, other indications
POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →